FINWIRES · TerminalLIVE
FINWIRES

Well Health Technologies Price Target Raised to $6 at CIBC

By

CIBC Capital Markets raised its price target on Well Health Technologies (WELL.TO) to $6 from $5.50.

Analyst Eric Kyle maintained an Outperformer rating on shares of the Vancouver-based digital health technology company.

"WELL announced the company has reached its $100 Million annualized adjusted EBITDA target for WELL Canada (Canadian clinics, WELLSTAR, and CYBERWELL) three quarters ahead of plan, in Q2/26 compared to Q1/27 expectations, driven by strong primary care organic growth and two accretive acquisitions," Kyle said in a note to clients.

"The company acquired an Ontario diagnostics imaging clinic and a Quebec procedural care clinic for $115 Million upfront, generating $22 Million of combined adjusted EBITDA, implying ~5x EBITDA on close," the analyst said.

"We expect management will increase 2026 guidance when WELL reports Q2 results in August."

Related Articles

Research

Research Alert: Macy's Q1 Fy 27 Beats Estimates With Growth Across Brands

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:M reported adjusted Q1 FY 27 (Jan.) EPS of $0.13 vs. $0.16 prior year, $0.10 above consensus estimates, on net sales of $4.682B (+1.8% Y/Y) and $70M above estimates. Comparable sales growth of 3.0% marked the strongest Q1 performance in four years and the fourth consecutive quarter of gains. The quarter showed broad-based strength with Bloomingdale's leading at 10.2% comparable sales growth, Macy's nameplate delivering 1.6% growth, and Bluemercury contributing 6.4% growth. Management raised full-year guidance with net sales of $21.5B-$21.75B, comparable sales of +0.5% to +1.2%, and adjusted EPS of $2.00-$2.20. The company returned $100M to shareholders while maintaining $1.3B in cash and a strong balance sheet position. Shares trade around 10x full-year EPS guidance, well above its three- and five-year forward P/E multiples of 7.0x and 6.5x, respectively. In our opinion, this was a typical quarter where sales growth didn't lead to margin expansion, and we do not see a big margin expansion story ahead.

$M
Research

PharmaCorp Rx Initiated at Outperform, $0.70 Price Target at Raymond James

PharmaCorp Rx Inc. (PCRX.V) was rated Outperform with a $0.70 price target in new coverage at Raymond James.Analyst Fred Gatali initiated coverage of the Saskatoon, Saskatchewan-based retail pharmacy acquisition and ownership company.Gatali said PharmaCorp has access to more than 1,100 independently-owned pharmacies and holds a right-of-first-refusal to acquire them."In addition, the company has a retail collaboration agreement with McKesson Canada's 2,000+ independent pharmacies as a partner in supporting owners who are considering ownership changes or need longer-term capital solutions," the analyst said in a note to clients."Notable is what we consider to be a flexible exit structure PharmaCorp provides to sellers, which we view as an important element of its acquisition strategy, which may allow an owner to monetize their pharmacy, but remain involved in the business to preserve customer relationships, support staff continuity, and maintain a role in the local community."

$PCRX.V
Research

B. Riley Downgrades Yext to Neutral From Buy, Adjusts Price Target to $5 From $8

$YEXT